Physician profile
Jude Emelumba
NPI 1396185567
$2,445.80
in general payments reported to CMS, 2019-2025
15 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $633 · 2022: $420 · 2023: $539 · 2024: $386 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.11 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $284.87 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $199.81 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $199.41 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $196.07 | 2021-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $188.79 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $158.35 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $140.19 | 2021-2022 | |
| Alkermes, INC. | $127.69 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.96 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $89.29 | 2021-2024 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $71.86 | 2025 | Cobenfy |
| Almatica Pharma LLC | $57.92 | 2022-2023 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $26.43 | 2021-2022 | |
| Axsome Therapeutics, INC. | $18.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jude Emelumba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.